Finding protein and gene markers in blood, spinal fluid, and brain linked to Parkinson's
Multi-tissue High-throughput Proteomic and Genomic Study in Parkinson's Disease
['FUNDING_R01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-10913351
This project looks for proteins and genetic signals in blood, spinal fluid, and brain tissue that could help diagnose and understand Parkinson's disease in people living with the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10913351 on ClinicalTrials.gov |
What this research studies
You would be part of a project where researchers analyze thousands of blood, spinal fluid (CSF), and brain samples to find proteins and genes tied to Parkinson's. They will measure about 1,300 proteins in CSF and plasma and validate promising findings in brain tissue from donated autopsies. The team will combine these proteomic results with broad, unbiased genomic analyses to pick the strongest marker candidates. In total they plan to screen roughly 3,110 samples and then repeat the most promising tests in separate groups.
Who could benefit from this research
Good fit: Ideal candidates are people with a clinical diagnosis of Parkinson's disease who are willing to provide blood and/or cerebrospinal fluid samples and, if applicable, consider brain donation for research.
Not a fit: People without Parkinson's, those with other movement disorders not linked to Parkinson's biology, or individuals unwilling/unable to provide blood or CSF samples are unlikely to benefit directly from participating.
Why it matters
Potential benefit: If successful, this work could lead to blood or CSF tests that help diagnose Parkinson's earlier or track disease progression.
How similar studies have performed: Large-scale proteomic and genomic approaches have produced useful biomarkers in diseases like Alzheimer's, but reliable blood/CSF biomarkers for Parkinson's remain unproven, so this applies promising methods that are still novel for PD.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BENITEZ, BRUNO A. — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: BENITEZ, BRUNO A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer's disease patient